Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-05-31
2005-05-31
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252180, C514S253110, C514S253130
Reexamination Certificate
active
06900211
ABSTRACT:
Compounds of the formulaor a pharmaceutically acceptable salt or isomer thereof, wherein:Q, X and Z are CH or N;R, R4-R7and R13are H or alkyl;R1is H, alkyl, fluoroalkyl, R9-arylalkyl, R9-heteroarylalkyl, alkyl-SO2—, cycloalkyl-SO2—, fluoroalkyl-SO2—, R9-aryl-SO2—, R9-heteroaryl-SO2—, N(R22)(R23)—SO2—, alkyl-C(O)—, cycloalkyl-C(O)—, fluoroalkyl-C(O)—, R9-aryl-C(O)—, NH-alkyl-C(O)— or R9-aryl-NH—C(O)—;R2is H and R3is H, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, R9-aryl, R9-arylalkyl, R9-heteroaryl, or R9-heteroarylalkyl, and when X and Z are each CH, R3is alkoxy, R9-aryloxy, R9-heteroaryloxy, alkylC(O)O—, alkylaminoC(O)O—, alkylC(O)NR13—, alkylOC(O)NR13— or alkylaminoC(O)NR13—;or R2and R3together are ═O, ═NOR10, ═N—NR11R12or ═CH-alkyl;R8is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenymethyl, alpha-substituted benzyl or alpha-substituted heteroarylmethyl;R9-R12are as defined;are disclosed for the treatment of HIV, solid organ transplant rejection, graft v. host disease, inflammatory diseases, atopic dermatitis, asthma, allergies or multiple sclerosis, as well as pharmaceutical compositions and combinations with antiviral or anti-inflammatory agents.
REFERENCES:
patent: 5883096 (1999-03-01), Lowe et al.
patent: 5889006 (1999-03-01), Lowe et al.
patent: 5952349 (1999-09-01), Asberom et al.
patent: 5977138 (1999-11-01), Wang et al.
patent: 6037352 (2000-03-01), Lowe et al.
patent: 6066636 (2000-05-01), Kozlowski et al.
patent: 1 103 276 (2000-06-01), None
patent: WO 94/18192 (1994-08-01), None
patent: WO 97/16440 (1997-05-01), None
patent: WO 97/24324 (1997-07-01), None
patent: WO 99/04794 (1999-02-01), None
patent: WO 00/66558 (2000-11-01), None
patent: WO 00/66559 (2000-11-01), None
Bruhl et al. Journal of Immunology, vol. 166, p. 2420-2426 (2001).*
Balashov et al. Proc. Natl.Acad.Sci., USA, vol. 96, p. 6873-6878 (1999).*
Sorensen et al. Journal of Clinical Investigation, vol. 103, p. 807-815 (1999).*
Simpson et al. Journal of Neuroimmunology, vol. 108, p. 192-200 (2000).*
Sellebjerg et al. Journal of Neuroimmunology, vol. 102, p. 98-106 (2000).*
Barcellos et al. Immunogenetics, vol. 51, p. 281-288 (2000).*
Zang et al. Brain, vol. 123, p. 1874-1882 (2000).*
Wang et al. Rheumatology,vol. 43, p. 569-573 (2004).*
Cook, Reviews in Neurological Diseases, vol. 1, p. 37-40 (2004).*
Owen, Pulmonary Pharmacology & Therapeutics vol. 14, p. 193-202 (2001).*
Fischereder et al. The Lancet vol. 357, p. 1758-1761 (2001).*
Vincenti, American Journal of Transplantation vol. 2, p. 898-903 (2002) (Abstract).*
Vandamme et al,Antiviral Chemistry and Chemotherapy, 9(1998) p. 187-203.
Connor et al,Virology, 206(1995) p. 935-944.
Plater-Zyberk et al,Immunol, Let., 57(1997) p. 117-120.
Boiardi et al,Clinical and Experimental Rheumatology, 17, (1999) p. 419-425.
Hatano et al,Clin. Exp. Immunol., 117(1999) p. 237-243.
Raychaudhuri et al,International J. of Immunopharmacology, 20(1998) p. 661-667.
Chihara et al,J. Allergy Clin. Immunol., 100, 6, part 2 (1997) p. S52-S55.
Beck et al,J. Immunol., 159, 6 (1997) p. 2962-72.
Tagat et al,Bioorganic&Medicinal Chemistry Letters, 11(2001) 2143-2146.
Magatti Anita W.
Schering Corporation
LandOfFree
CCR5 antagonists useful for treating aids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CCR5 antagonists useful for treating aids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CCR5 antagonists useful for treating aids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3426727